Gilead keeps investing on cancer sector

Gilead has announced today to the financial community that it has signed an agreement with Netherlands-based Gadeta to develop a new range of TCR immunotherapies for the treatment of solid and blood cancer types. Thanks to the agreement, Gilead will fund the therapy development through its subsidiary Kite, which will make Gadeta payments upon completion of precise milestones. The agreement proves that Gilead aims at becoming a relevant player in the cancer sector. Gilead’s shares (Wall Street) have remained fairly unaltered as the deal was announced.

(Source: Gilead)